// App-Quantinova.ai

E089 : Effect of secukinumab on radiographic progression and inflammation in sacroiliac joints and spine in patients with non-radiographic axial spondyloarthritis: 2-year imaging outcomes from a Phase III randomised trial

Researchers

Presenter

  • Helena Marzo-Ortega

Principal Investigators

  • Juergen Braun

  • Ricardo Blanco

  • Lianne S Gensler

  • Filip van Den Bosch

  • Stephen Hall

  • Hideto Kameda

  • Denis Poddubnyy

  • Marleen G H van de Sande

  • Désirée van der Heidje

  • Tingting Zhuang

  • Anna Stefanska

  • Aimee Readie

  • Hanno Richards

  • Atul Deodhar

Medical Centers

  • Division of Hematology, Showa University, Tokyo, Japan

  • Center for Inflammation Research, UGent-VIB, Ghent, Belgium

  • Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany

  • Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin, and Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany

  • Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain

  • Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR

  • Department of Rheumatology and Clinical Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands

  • Department of Immunology, Monash University, Melbourne, Australia

  • Department of Internal Medicine and Pediatrics,Ghent University,Gent,Belgium

  • Dept. of Dermatology, Ruhr University of Bochum, Bochum, Germany

  • NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom

  • Department of Pathology, University of California, San Francisco, CA

  • Novartis Pharmaceuticals AG, Basel, Switzerland

  • Department of Urology, Leiden Unviersity Medical Center, Leiden, Netherlands

Locations

  • Japan

  • Australia

  • Belgium

  • United States

  • Germany

  • United Kingdom

  • Spain

  • Switzerland

  • Netherlands

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Non-radiographic axial spondyloarthritis

  • Ankylosing spondylitis

  • Spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved